- A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab(TM)) in High-Risk Patients with Percutaneous Coronary Intervention
-
Moon JY, Kim W, Kim JH, Ahn Y, Jeong MH, Kim YH, Hong MK, Park SW, Park SJ, Park S, Ko YG, Choi D, Jang Y
- KMID: 724253
- Yonsei Med J.
- 2008 Jun;49(3):389-399.
- doi: 10.3349/ymj.2008.49.3.389
PURPOSE: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab(TM). We expected to obtain same results as with ReoPro(R) in improving... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro (R) ), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
-
Sim DS, Jeong MH, Kim W, Rhew JY, Yum JH, Kim JH, Cho JG, Ahn YK, Park JC, Ahn BH, Kim SH, Kang JC
- KMID: 759651
- Korean J Intern Med.
- 2003 Sep;18(3):129-137.
BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
-
Cho JS, Her SH, Baek JY, Park MW, Kim HD, Jeong MH, Ahn YK, Chae SC, Hur SH, Hong TJ, Kim YJ, Seong IW, Chae JK, Rhew JY, Chae IH, Cho MC, Bae JH, Rha SW, Kim CJ, Choi D, Jang YS, Yoon J, Chung WS, Cho JG, Seung KB, Park SJ
- KMID: 1779230
- J Korean Med Sci.
- 2010 Nov;25(11):1601-1608.
- doi: 10.3346/jkms.2010.25.11.1601
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with... -
- CITED
-
- Close
- SHARE
-
- Close
